Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Alzheimer’s disease

- PMLiVE

Bristol Myers Squibb’s Breyanzi granted FDA accelerated approval for follicular lymphoma

The disease accounts for up to 30% of all non-Hodgkin lymphoma cases

Biogen Idec building

Biogen and Eisai announce rolling FDA submission for injectable version of Alzheimer’s drug

The Leqembi SC autoinjector could reduce the need for hospital visits and nursing care compared to IV administration

- PMLiVE

Roche announces FDA approval of self-collection solution for HPV screening

More than 13,000 people are diagnosed with cervical cancer every year in the US

- PMLiVE

Takeda gains exclusive option for AC Immune’s Alzheimer’s drug candidate in deal worth over $2.1bn

The agreement includes an option to licence global rights to the anti-amyloid beta immunotherapy

- PMLiVE

Study reveals two copies of APOE4 gene could increase risk of developing Alzheimer’s

The progressive neurodegenerative disease is the most common form of dementia

- PMLiVE

Pfizer/Genmab’s Tivdak granted full FDA approval for recurrent or metastatic cervical cancer

It is estimated that more than 13,960 new cases of invasive cervical cancer were diagnosed in the US last year

- PMLiVE

Pfizer’s one-time haemophilia B therapy Beqvez granted FDA approval

More than 38,000 people worldwide are currently affected by the rare genetic bleeding disorder

Biogen Idec building

Biogen’s tocilizumab biosimilar Tofidence recommended by CHMP to treat arthritis and COVID-19

The committee’s decision was supported by evidence demonstrating Tofidence’s similarity to Roche’s RoActemra

- PMLiVE

Novartis’ Lutathera receives FDA approval to treat neuroendocrine tumours in paediatric patients

The incidence of neuroendocrine tumours has increased over the past several decades

- PMLiVE

FDA grants Day One’s Ojemda accelerated approval for paediatric low-grade glioma

The type 2 RAF inhibitor is the first and only one approved in the US to treat this patient population

- PMLiVE

FDA approves ImmunityBio’s Anktiva for non-muscle invasive bladder cancer

NMIBC accounts for up to 80% of bladder cancer cases, the tenth most commonly diagnosed cancer globally

- PMLiVE

Eisai and BioArctic sign research evaluation agreement for potential new Alzheimer’s treatment

AD is the most common form of dementia, which affects around 55 million people globally

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links